Phaseline

Companies › Myeloid Therapeutics

Myeloid Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Immunology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MT-304
mRNA-LNP encoding HER2-targeted immunotherapy
ERBB2Phase 1HER2-Expressing Solid TumorsJan 2027
MT-302–Phase 1Epithelial Tumors, MalignantAug 2027
MT-303
anti-GPC3 antibody-drug conjugate
–Phase 1Hepatocellular CarcinomaDec 2027
CRT-402
CD19-targeted CAR-T cell therapy designed to deplete CD19-positive B cells
CD19Phase 1Autoimmune DiseasesDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07334119MT-304Phase 1HER2-Expressing Solid TumorsOncologyJan 2027
NCT05969041MT-302Phase 1Epithelial Tumors, MalignantOncologyAug 2027
NCT06478693MT-303Phase 1Hepatocellular CarcinomaOncologyDec 2027
NCT07778446CRT-402Phase 1Autoimmune DiseasesImmunologyDec 2028

Targets

CD19 (1) ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics AstraZeneca Miltenyi Biomedicine Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.